{"nctId":"NCT01880736","briefTitle":"A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes","startDateStruct":{"date":"2013-06"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":458,"armGroups":[{"label":"IDeg OD Flexible Dose","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec"]},{"label":"IDeg OD Fixed Dose","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec"]},{"label":"IDeg OD Simple","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec"]},{"label":"IDeg OD Stepwise","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec"]}],"interventions":[{"name":"insulin degludec","otherNames":[]},{"name":"insulin degludec","otherNames":[]},{"name":"insulin degludec","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Current treatment with IGlar (insulin glargine) with or without OADs (oral antidiabetic drug). All antidiabetic treatments should have been on-going for at least 12 weeks prior to randomisation, and doses of OADs should have been stable in this period of time. - Please note that a maximum of 3 OADs are allowed during this trial: metformin, sulphonylurea (SU)/glinides, dipeptidyl peptidase 4 (DPP-IV) inhibitors, alfa-glucosidaseinhibitors or pioglitazone.\n* Diagnosis of T2DM (type 2 diabetes mellitus) at the discretion of the investigator for at least 26 weeks prior to visit 1 (Screening visit)\n* HbA1c 7.0-9.5% (both inclusive) by central laboratory analysis\n* Body mass index (BMI) equal to or below 35 kg/m\\^2\n\nExclusion Criteria:\n\n* Any chronic disorder or severe disease which, in the opinion of the Investigator might jeopardise subject's safety or compliance with the protocol\n* Stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty; all within the last 26 weeks prior to Visit 1 (Screening visit)\n* Impaired renal function, defined as serum-creatinine higher than or equal to 1.4 mg/dL for males and higher than or equal to 1.3 mg/dL for females\n* Current or past (within the last 5 years) malignant neoplasms (except basal cell and squamous cell skin carcinoma)\n* Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria in a period of 12 weeks prior to randomisation","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c (%) Glycosylated Haemoglobin)","description":"Changes from baseline in HbA1c values over time period of Week 0-26 were evaluated by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","spread":"0.76"},{"groupId":"OG001","value":"-0.62","spread":"0.75"},{"groupId":"OG002","value":"-0.57","spread":"0.72"},{"groupId":"OG003","value":"-0.59","spread":"0.80"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG)","description":"Changes from baseline in FPG values over the time period of Week 0-26 were evaluated by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.8","spread":"39.0"},{"groupId":"OG001","value":"-25.4","spread":"40.2"},{"groupId":"OG002","value":"-27.0","spread":"35.3"},{"groupId":"OG003","value":"-27.2","spread":"43.6"}]}]}]},{"type":"SECONDARY","title":"Responder for HbA1c (%) Based on Central Laboratory Assessment: HbA1c Below 7.0% at End of Trial","description":"The number of subjects who achieved the pre-defined HbA1c target (\\<7.0%) after 26 weeks of treatment was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"91","spread":null},{"groupId":"OG003","value":"94","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Treatment Emergent Adverse Events (TEAEs)","description":"The incidences of treatment emergent adverse events (TEAEs) over the time period of Week 0-26 were recorded by dosing regimen (flexible vs. fixed dosing); and by titration algorithm (simple vs stepwise).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":null},{"groupId":"OG001","value":"154","spread":null},{"groupId":"OG002","value":"138","spread":null},{"groupId":"OG003","value":"166","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Confirmed Hypoglycaemic Episodes (Defined as Severe Hypoglycaemia and/or a Measured Plasma Glucose (PG) Less Than 3.1 mmol/L (Less Than 56 mg/dL))","description":"The confirmed hypoglycaemic episodes (defined as severe hypoglycaemia and/or a measured plasma glucose (PG) less than 3.1 mmol/L \\[less than 56 mg/dL\\]) over the time period of Week 0-26 was recorded by dosing regimen (flexible vs. fixed dosing); and by titration algorithm (simple vs stepwise).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"476","spread":null},{"groupId":"OG001","value":"371","spread":null},{"groupId":"OG002","value":"469","spread":null},{"groupId":"OG003","value":"378","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association (ADA) Definition","description":"Number of treatment emergent hypoglycaemic episodes according to the ADA definition (classified as severe hypoglycaemia, documented hypoglycaemia, asymptomatic hypoglycaemia, probable symptomatic hypoglycaemia, relative hypoglycaemia) over the time period of Week 0-26 was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3053","spread":null},{"groupId":"OG001","value":"2736","spread":null},{"groupId":"OG002","value":"3089","spread":null},{"groupId":"OG003","value":"2700","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1262","spread":null},{"groupId":"OG001","value":"1141","spread":null},{"groupId":"OG002","value":"1293","spread":null},{"groupId":"OG003","value":"1110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1523","spread":null},{"groupId":"OG001","value":"1283","spread":null},{"groupId":"OG002","value":"1505","spread":null},{"groupId":"OG003","value":"1301","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"131","spread":null},{"groupId":"OG002","value":"103","spread":null},{"groupId":"OG003","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"181","spread":null},{"groupId":"OG001","value":"180","spread":null},{"groupId":"OG002","value":"187","spread":null},{"groupId":"OG003","value":"174","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Confirmed Hypoglycaemic Episodes in the Maintenance Period","description":"The number of treatment mergent confirmed hypoglycaemic episodes in the maintenance period from Week 16 to end of trial (week 27) was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs. stepwise). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"227","spread":null},{"groupId":"OG001","value":"192","spread":null},{"groupId":"OG002","value":"241","spread":null},{"groupId":"OG003","value":"178","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes","description":"The number of treatment emergent nocturnal (00:01-05:59 am) confirmed hypoglycaemic episodes over the time period of Week 0-26 was recorded by dosing regimen (flexible vs. fixed dosing) and by titration algorithm (simple vs stepwise). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"80","spread":null},{"groupId":"OG003","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes in the Maintenance Period","description":"The number of treatment emergent nocturnal (00:01-05:59 am) confirmed hypoglycaemic episodes in the maintenance period from 16 weeks to end of trial (week 27) was recorded by dosing regimen (flexible vs. fixed dosing); and by titration algorithm (simple vs stepwise). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed plasma glucose value of less than 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"40","spread":null},{"groupId":"OG003","value":"17","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":229},"commonTop":["Nasopharyngitis","Diabetic retinopathy"]}}}